Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new gel make eye injections less painful?

NCT ID NCT07779356

Symptom relief Sponsor: Retina Consultants of Delmarva Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether a new anesthetic gel, Iheezo, reduces discomfort during intravitreal injections compared to standard numbing drops. Fifty patients receiving injections in both eyes on the same day will have one eye treated with Iheezo and the other with standard anesthesia. They will rate their pain at several time points after the injection to see which method is more comfortable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Iheezo (a topical anesthetic gel) compared with standard anesthesia (proparacaine drops plus lidocaine pledget)
What this could lead to
If Iheezo proves more comfortable, it could become a preferred anesthetic for eye injections, improving patient experience.
What could go wrong
This is a small, single-center study, and results may not apply broadly. Individual comfort varies, and Iheezo might not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Started

May 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Anyone receiving bilateral same day intravitreal injections as standard care Exclusion Criteria: * Inability to complete post-injection survey * History of receiving Iheezo

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy macular degeneration retinal vein occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy Macular degeneration Retinal vein occlusion (RVO)

Contacts and locations

Locations

  • Retina Consultants of Delmarva

    Easton, Maryland, 21601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.